Abdulsamad Molham, Reddy Pavithra, Guvvala Suvarna, Dev Anil
Department of Medicine, Division of Gastroenterology, Bronx Lebanon Hospital Center, 1650 Selwyn Avenue, Suite# 10C, Bronx, NY 10457, USA.
Gastroenterology Res. 2017 Apr;10(2):144-146. doi: 10.14740/gr812w. Epub 2017 Apr 19.
Endoscopic retrograde cholangiopancreatography (ERCP) is a procedure that combines the use of endoscopy and fluoroscopy to diagnose and treat pancreaticobiliary disorders. The risks of ERCP include pancreatitis, infection, bleeding and perforation. Bleeding during ERCP typically develops after sphincterotomy, hence patients should be screened and tested for coagulopathy before undergoing ERCP. Coagulopathy is a major risk factor for ERCP-related bleeding. Inherited factor VII (FVII) deficiency is a rare autosomal recessive hemorrhagic disorder that can lead to significant coagulopathy and severe bleeding if not appropriately recognized and treated preoperatively. Clinically, the disease ranges between an asymptomatic state to lethal hemorrhage and the degree of FVII deficiency does not correlate with the severity of bleeding. The use of FVII replacement therapy has been reported to prevent bleeding during surgery. We present the first report of a patient with a rare cause of coagulopathy due to inherited FVII deficiency who successfully underwent ERCP with sphincterotomy without bleeding where we used recombinant factor VIIa before and after the procedure.
内镜逆行胰胆管造影术(ERCP)是一种将内镜检查与荧光透视相结合以诊断和治疗胰胆管疾病的操作。ERCP的风险包括胰腺炎、感染、出血和穿孔。ERCP期间的出血通常在括约肌切开术后发生,因此患者在接受ERCP之前应进行凝血功能障碍的筛查和检测。凝血功能障碍是ERCP相关出血的主要危险因素。遗传性因子VII(FVII)缺乏症是一种罕见的常染色体隐性出血性疾病,如果术前未得到适当认识和治疗,可导致严重的凝血功能障碍和严重出血。临床上,该疾病的范围从无症状状态到致命性出血,FVII缺乏的程度与出血的严重程度无关。据报道,使用FVII替代疗法可预防手术期间的出血。我们报告了首例因遗传性FVII缺乏导致凝血功能障碍的患者,该患者成功接受了括约肌切开术的ERCP且未出血,我们在手术前后使用了重组因子VIIa。